Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...

In 2022, in-shoe sensors emerged as the leading product in the market, accounting for a significant 34.5% share. These ...